15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 2 of 15

 
 

Novo Nordisk A/S (NYSE:NVO)

Consensus Rating
Moderate Buy
Rating Score
2.8
Ratings Breakdown
6 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$133.60 (3.9% Upside)

About Novo Nordisk A/S

Novo Nordisk A/S logoNovo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
4/18/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
4/12/2024BMO Capital MarketsInitiated CoverageOutperform$163.00
4/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
3/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
2/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00
2/14/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00
2/1/2024Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$120.00 ➝ $140.00
1/23/2024Morgan StanleyInitiated CoverageOverweight$120.00
1/16/2024UBS GroupInitiated CoverageNeutral
1/12/2024Cantor FitzgeraldReiterated RatingOverweight
 

Global crypto currency reset (41 major banks signed up) (Ad)

Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...

 Here's everything you need to know.